Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Optomed Q2: Revenue growth, expanding margins

2021-08-05

15:44

GA

Gergana Almquist

Redeye maintains at this point Optomed's valuation at EUR 13 per share after the strong Q2 report. We expect the company to continue delivering solid results this year, followed by stronger growth in 2022, both of camera and of software revenues, and further improving gross margins.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers